Long-Term Visual Field Outcomes After Ahmed Glaucoma Valve Implantation.

Abstract

To measure visual field (VF) rates of change after Ahmed Glaucoma Valve (AGV) implantation and to investigate risk factors for progression. Retrospective, clinical cohort study. Patients who underwent AGV implantation with at least 4 eligible postoperative VFs and 2 years of follow-up were included. Baseline, intraoperative, and postoperative data were collected. VF progression was explored with 3 methods: mean deviation (MD) rate; glaucoma rate index (GRI); and pointwise linear regression (PLR). For a subset of eyes with sufficient preoperative and postoperative VFs, rates were compared between the 2 periods. A total of 173 eyes were included. The intraocular pressure (IOP) and number of glaucoma medications were significantly reduced from a median (interquartile range [IQR]) of 23.5 (12.1) mm Hg at baseline to 12.8 (4.0) mm Hg at final follow-up, and from (mean ± SD) 3.3 ± 1.2 to 2.2 ± 1.4, respectively. A total of 38 eyes (22%) showed VF progression, and 101 eyes (58%) were stable as assessed by all 3 methods, which accounted for 80% of all eyes. The rate of VF decline by MD and GRI was a median (IQR) of -0.30 (0.8) dB/y and -2.30 (10.6) (of -100), respectively. When comparing progression before and after surgery, the reduction was not statistically significant with any of the methods. The peak IOP (after 3 postoperative months) was associated with VF deterioration, with a 7% increase in risk per each additional millimeter of mercury (mm Hg). To our knowledge, this is the largest published series reporting long-term VF outcomes after glaucoma drainage device implantation. There is a continued, significant rate of VF decline after AGV surgery.